Literature DB >> 30326982

COST, CONTEXT, AND DECISIONS IN HEALTH ECONOMICS AND HEALTH TECHNOLOGY ASSESSMENT.

Anthony J Culyer1.   

Abstract

OBJECTIVES: This study is an attempt to demystify and clarify the idea of cost in health economics and health technology assessment (HTA).
METHODS: Its method draws on standard concepts in economics. Cost is a more elusive concept than is commonly thought and can be particularly elusive in multidisciplinary territory like HTA.
RESULTS: The article explains that cost is more completely defined as opportunity cost, why cost is necessarily associated with a decision, and that it will always vary according to the context of that decision: whether choice is about inputs or outputs, what the alternatives are, the timing of the consequences of the decision, the nature of the commitment to which a decision maker is committed, who the decision maker is, and the constraints and discretion limiting or liberating the decision maker. Distinctions between short and long runs and between fixed and variable inputs are matters of choice, not technology, and are similarly context-dependent. Harms or negative consequences are, in general, not costs. Whether so-called "clinically unrelated" future costs and benefits should be counted in current decisions again depends on context.
CONCLUSIONS: The costs of entire health programs are context-dependent, relating to planned rates of activity, volumes, and timings. The implications for the methods of HTA are different in the contexts of low- and middle-income countries compared with high-income countries, and further differ contextually according to the budget constraints (fixed or variable) facing decision makers.

Keywords:  Context; Fixed/variable costs; LMICs; Opportunity cost; Short/long runs; Unrelated costs

Mesh:

Year:  2018        PMID: 30326982     DOI: 10.1017/S0266462318000612

Source DB:  PubMed          Journal:  Int J Technol Assess Health Care        ISSN: 0266-4623            Impact factor:   2.188


  5 in total

1.  Incorporating Future Medical Costs: Impact on Cost-Effectiveness Analysis in Cancer Patients.

Authors:  Michelle Tew; Philip Clarke; Karin Thursky; Kim Dalziel
Journal:  Pharmacoeconomics       Date:  2019-07       Impact factor: 4.981

2.  Patients' out-of-pocket expenses analysis of presurgical teledermatology.

Authors:  Felipa de Mello-Sampayo
Journal:  Cost Eff Resour Alloc       Date:  2019-08-23

3.  Are Estimates of the Health Opportunity Cost Being Used to Draw Conclusions in Published Cost-Effectiveness Analyses? A Scoping Review in Four Countries.

Authors:  Laura Vallejo-Torres; Borja García-Lorenzo; Laura Catherine Edney; Niek Stadhouders; Ijeoma Edoka; Iván Castilla-Rodríguez; Lidia García-Pérez; Renata Linertová; Cristina Valcárcel-Nazco; Jonathan Karnon
Journal:  Appl Health Econ Health Policy       Date:  2021-12-29       Impact factor: 3.686

Review 4.  Supply-Side Cost-Effectiveness Thresholds: Questions for Evidence-Based Policy.

Authors:  Chris Sampson; Bernarda Zamora; Sam Watson; John Cairns; Kalipso Chalkidou; Patricia Cubi-Molla; Nancy Devlin; Borja García-Lorenzo; Dyfrig A Hughes; Ashley A Leech; Adrian Towse
Journal:  Appl Health Econ Health Policy       Date:  2022-06-07       Impact factor: 3.686

Review 5.  Conducting Value for Money Analyses for Non-randomised Interventional Studies Including Service Evaluations: An Educational Review with Recommendations.

Authors:  Matthew Franklin; James Lomas; Gerry Richardson
Journal:  Pharmacoeconomics       Date:  2020-07       Impact factor: 4.981

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.